Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Lymphoma 27Lymphoma, Non-Hodgkin 24Leukemia, Lymphocytic, Chronic, B-Cell 24Lymphoma, Mantle-Cell 23Lymphoma, Follicular 17Lymphoma, Large B-Cell, Diffuse 15Multiple Myeloma 14Recurrence 13Hodgkin Disease 12Lymphoma, B-Cell, Marginal Zone 7Leukemia 7Waldenstrom Macroglobulinemia 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Neoplasms, Plasma Cell 4Neoplasms 4Leukemia, B-Cell 4Hematologic Neoplasms 4Myeloproliferative Disorders 3Myelodysplastic Syndromes 3Lymphoma, T-Cell, Peripheral 3Lymphoma, T-Cell 3Lymphoma, B-Cell 3Leukemia, Myeloid, Acute 3Leukemia, Lymphoid 3Small Cell Lung Carcinoma 2Leukemia, Biphenotypic, Acute 2Burkitt Lymphoma 2Sezary Syndrome 1Sarcoma 1Renal Insufficiency, Chronic 1

Interventions

Radiotherapy 54Temozolomide 50Filgrastim 25Cyclophosphamide 25Etoposide 24Cisplatin 22Carboplatin 22Vincristine 19Chemotherapy, Adjuvant 18Peripheral Blood Stem Cell Transplantation 15Thiotepa 13Carmustine 12Thalidomide 10Methotrexate 9Magnetic Resonance Spectroscopy 9Irinotecan 9Bevacizumab 9Granulocyte Colony-Stimulating Factor 7sargramostim 6Topotecan 6Lomustine 6X-Rays 5Tamoxifen 5Specimen Handling 5Phantoms, Imaging 5O(6)-benzylguanine 5Ifosfamide 5Erlotinib Hydrochloride 5Drug Therapy 5Celecoxib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Central Nervous System Neoplasms × Bendamustine Hydrochloride × Clear all
NCT04792489 2025-04-24

DALY II USA/ MB-CART2019.1 for DLBCL

Miltenyi Biomedicine GmbH

Phase 2 Recruiting
248 enrolled
CNSLymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡